



Clinical Justification – New-to-Market Medication
Fax to BMC HealthNet Plan PA Dept. 617-897-0800
BMC HealthNet Plan PA Dept. Phone 1-800-900-1451

Product Applicability: MassHealth Commonwealth Care Commercial

PRESCRIBER INFORMATION

Name: _____ Specialty: _____
 Office Contact: _____ NPI#: _____
 Phone: _____ Fax: _____ Prescriber Signature: _____
 Address: _____ City: _____ State: _____ Zip Code: _____

PATIENT INFORMATION

Name: _____ Date: _____
 DOB: _____ Member BMCHP ID: _____
Diagnosis: _____ **Medication & Dose Requested:** _____

Medications managed under the **New-to-Market Medication Program** are indicated on the BMC HealthNet Plan formulary, available at www.bmchp.org. These medications require prior authorization until formally reviewed by BMC HealthNet Plan’s Pharmacy & Therapeutics (P&T) Committee.

New-to-market medications require documentation of inadequate clinical response and/ or intolerance to at least *two* formulary alternatives within the same therapeutic sub-category AND *two* other formulary alternatives clinically appropriate for the condition for which the member is being treated, OR all other currently accepted therapeutic options if the medication is the first in its therapeutic class or if it is a new indication for the medication.

Please list covered alternative medications tried and failed to treat the above condition		
Medication/Dose/Frequency	Start and End Date of Therapy	Ineffective/Complications/Others (specify below)

Additional information / relevant comments:

This transmission may contain protected health information, which is transmitted pursuant to an authorization or as permitted by law. The information herein is confidential and intended only for use by the designated recipient who/which must maintain its confidentiality and security. If you are not the designated recipient, you are strictly prohibited from disclosing, copying, distributing, or taking action in reliance on the contents hereof. If you have received this transmission in error, please notify the sender immediately and arrange for the return or destruction of all of its contents. Unauthorized re-disclosure of confidential health information is prohibited by state and federal law.